Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 1, 2024Journal for ImmunoTherapy of CancerOpen Access

Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

HZHesong ZouWLWei LiuXWXiaojuan Wang

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Zou et al. (2024) studied this question.

synapsesocial.com/papers/68e761b8b6db6435876d7a3fhttps://doi.org/10.1136/jitc-2023-008450
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world evaluation of ctdna for risk stratification across the spectrum of both aggressive and indolent lymphomas2025 · 1 citations
  2. 2Longitudinal ctdna tracking by low-pass whole-genome sequencing during CD19 CAR-T cell therapy for B-cell lymphomas2025
  3. 3Whole-genome sequencing (WGS)-based circulating tumor DNA (ctDNA) monitoring in diffuse-large B-cell lymphoma (DLBCL)2025
  4. 4Clinical Implication of Sequential Circulating Tumor DNA Assessments for the Treatment of Diffuse Large B-Cell Lymphoma2025 · 1 citations
  5. 5Circulating Tumor DNA as a Complementary Prognostic Biomarker during CAR-T Therapy in B-Cell Non-Hodgkin Lymphomas2024 · 6 citations